UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                  ------------

                                    FORM 8-K

                                  ------------

                                 CURRENT REPORT

                       Pursuant to Section 13 or 15(d) of
                       the Securities Exchange Act of 1934

                Date of Report (Date of Earliest Event Reported):
                                  July 19, 2005


                           USANA HEALTH SCIENCES, INC.
             (Exact name of registrant as specified in its charter)

                           Commission File No. 0-21116

                   Utah                                    87-0500306

      (State or other jurisdiction                (IRS Employer Identification

             of incorporation)                               Number)

                           3838 West Parkway Boulevard
                           Salt Lake City, Utah 84120
               (Address of principal executive offices, Zip Code)

       Registrant's telephone number, including area code: (801) 954-7100

   Former name or former address, if changed since last report: Not Applicable



Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

[ ]  Written communications pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))







Item 2.02    Results of Operations and Financial Condition

On July 19, 2005, USANA Health Sciences, Inc. issued a press release announcing
its financial results for the second quarter ended July 2, 2005. The release
also announced that executives of the company would discuss these results with
investors on a conference call broadcast over the World Wide Web and by
telephone and provided access information, dates and times for the conference
call. A copy of the press release is furnished herewith as Exhibit 99 to this
Current Report on Form 8-K and is incorporated herein by reference. The company
will also post this document on its corporate Web site,
www.usanahealthsciences.com, under the "investors" link.

The information in this Current Report is being furnished and shall not be
deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of
1934, as amended, or otherwise subject to the liabilities of that Section. The
information in this Current Report shall not be incorporated by reference into
any registration statement or other document pursuant to the Securities Act of
1933, as amended. The furnishing of the information in this Current Report is
not intended to, and does not, constitute a representation that such furnishing
is required by Regulation FD or that the information this Current Report
contains is material investor information that is not otherwise publicly
available.


Item 9.01    Financial Statements and Exhibits (furnished herewith)

             (c)     Exhibits

Exhibit 99   Press release issued by USANA Health Sciences, Inc. dated July 19,
             2005.






                                       2



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                     USANA HEALTH SCIENCES, INC.


                                     By: /s/ Gilbert A. Fuller
                                         ---------------------
                                     Gilbert A. Fuller, Chief Financial Officer

Date: July 20, 2005






                                       3